Health Condition 1: R05- Cough
Conditions
Interventions
Intervention1: Habb-e-Baqla: 2 tabs 500mg (each) twice daily orally for 14 days.
Control Intervention1: Sharbat e Ejaz: 20 ml twice daily with lukewarm water for 14 days
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Dry cough with onset not more than 3 weeks with/without Khushunat e Halq.
Exclusion criteria
Exclusion criteria: 1. Any specific symptoms that signify any history of serious lower respiratory tract infection, such as pneumonia, lung abscess, bronchiectasis, emphysema, pneumothorax, hydrothorax, COPD, or pulmonary tuberculosis. 2. Cough associated with high-grade fever. 3. Known cases of any other clinically significant comorbid conditions, like severe renal,hepatic and cardiovascular disorders. 4. Known cases of immunocompromised conditions such as HIV/AIDS, cancer, etc. 5. Diabetes mellitus, hypertension or any other systemic disorders requiring prolonged treatment. 6. Pregnant and lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety and efficacy of Unani Pharmacopeial formulation Habbe Baqla in comparison with Sharbat e Ejaz in Sual (Cough) will be carried out on the basis of a cough Visual Analogue Scale (VAS), Khushunat e Halq (Visual analogue scale) and Cough Symptom Score (CSS).Timepoint: At 7th and 14th day of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical investigations for safety assessment i.e., Hemogram, Urine Examination: Routine & Microscopic.Timepoint: At baseline, first follow up and at the end of treatment. i.e., 0, 7th and 14th day | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed